Evaluation of immunogenicity after first dose of hepatitis B vaccine in newborns with very low birth weight

Figures & data

Table 1. Diagnostic data of the subjects in the study (Mean ± SEM)

Diagnostic	Normal (>2000 g) (n = 30)	Case (<2000 g) (n = 30)
Birth weight (g)	2976 ± 84,8	1054 ± 44,5
Gender, women/men, (n)	16/14	12/18
Antenatal steroid use, (n)	0	30
Gestational age (weeks)	38,4 ± 1,2	27,67 ± 2,09
First vaccine weight (g)	2976 ± 84,8	1446 ± 47,94
Postnatal surfactant		30
Maternal age (years)	28,77 ± 6,5	28,03 ± 4,7
Vaccination age (weeks)	38,4 ± 1.2	31,73 ± 2.08
Antibody levels (ıu/L)	276,7 ± 66,8	335,5 ± 61,72
Respiratory distress syndrome, (n)	0	30
İntravenous antibiotics, (n)	0	30
Blood transfusion, (n)	0	14
Pulmonary hypertension, (n)	0	8
İntracranial bleeding, (n)	0	7
Hydrocephalus, (n)	0	5
Necrotizing enterocolitis, (n)	0	4
Seizure, (n)	0	3

Figure 1. Hepatitis antibody level comparing between normal (>2000 g) and the case (<2000 gr). P value <.005 is accepted as significantly different and data presented as means with standard error of the mean.

Figure 2. Hepatitis antibody level comparing between first vaccine weight >2500 g and first vaccine weight <2500 gr. P value <.005 is accepted as significantly different and data presented as means with standard error of the mean.

Figure 3. Hepatitis antibody level comparing between first vaccine weight >1500 g and first vaccine weight <1500 gr. P value <.005 is accepted as significantly different and data presented as means with standard error of the mean.